[1]
黄华芳, 熊开钧, 何生松, 李瑗, 王萍, 蔡淑清, 曾令兰, 王心禾, 1991: The Observation on the Antiviral Effect of Ribavirin and Combining with Interferon in Patients with Chronic Hepatitis B, Virologica Sinica, 6, 201-.
[2]
朱智勇, 唐汉英, 李岩金, 翁景清, 陆群英, 李敏红, 俞永新, 刘文雪, 曾蓉芳, 舒浩麒, 1992: Observation on Effect of Secondary Immune with Inactivated EHF Vaccine, Virologica Sinica, 7, 404-.
[3]
马立宪, 倪大石, 董朝阳, 王灵枢, 1991: Finding of Fusion Cells from the EHF Patients Urine and Its Significance, Virologica Sinica, 6, 117-.
[4]
聂子林, 俞永新, 刘文雪, 1992: Serotyging of EHF Viruses and Serotygic diagnosis of Patients by Micro--CPE Neutralization Test (MCPENT), Virologica Sinica, 7, 27-.
[5]
叶苓, 杨守京, 刘彦仿, 晏培松, 1998: Localization and distribution of HSP70 mRNA and Hantann virus in autopsy tissue of the patients with EHF and in virus-infected cells, Virologica Sinica, 13, 332-.
[6]
张天明, 向近敏, 1988: Detections and Dynamic Study of C3 and C4 in EHF Patients, Virologica Sinica, 3, 333-.
[7]
Wei-wei Gai, Yan Zhang, Di-han Zhou, Yao-qing Chen, Jing-yi Yang, Hui-min Yan, 2011: PIKA Provides an Adjuvant Effect to Induce Strong Mucosal and Systemic Humoral Immunity Against SARS-CoV^*, Virologica Sinica, 26, 81-94. doi: 10.1007/s12250-011-3183-z
[8]
吴伟忠, 杨英珍, 金佩英, 1992: Effect of Astragalus Membranaceus on T Lymphocyte Mediated Immunity in Mice with Coxsackie B3 Viral Myocarditis, Virologica Sinica, 7, 129-.
[9]
Xingyu Wang, Kun Huang, Haini Jiang, Lijuan Hua, Weiwei Yu, Dan Ding, Ke Wang, Xiaopan Li, Zhong Zou, Meilin Jin, Shuyun Xu, 2020: Long-Term Existence of SARS-CoV-2 in COVID-19 Patients: Host Immunity, Viral Virulence, and Transmissibility, Virologica Sinica, 35, 793-802. doi: 10.1007/s12250-020-00308-0
[10]
黄华芳, 熊开钧, 王心禾, 曾令兰, 刘彼息, 曾凡珍, 吴章琦, 1990: Followed-up Observation on Antiviral Effect of Combined Treatment of Small Dosage of Interferon and Thymosin in Patients with Chronic Hepatitis B, Virologica Sinica, 5, 69-.
[11]
冯志华, 周永兴, 焦成松, 王全楚, 李谨革, 贾战生, 李文渡, 杜德伟, 2001: Enhancing Effect of Thl Cytokine on Imm une Responses of M ice to Recom binant Plasmid Encoding Hepatitis C Virus Core Gene, Virologica Sinica, 16, 101-104.
[12]
Yang Zheng, Qing Zhang, Ashaq Ali, Ke Li, Nan Shao, Xiaoli Zhou, Zhiqin Ye, Xiaomin Chen, Shanshan Cao, Jing Cui, Juan Zhou, Dianbing Wang, Baidong Hou, Min Li, Mengmeng Cui, Lihua Deng, Xinyi Sun, Qian Zhang, Qinfang Yang, Yong li, Hui Wang, Yake Lei, Bo Yu, Yegang Cheng, Xiaolin Tong, Dong Men, Xian-En Zhang, 2021: Sustainability of SARS-CoV-2 Induced Humoral Immune Responses in COVID-19 Patients from Hospitalization to Convalescence Over Six Months, Virologica Sinica, 36, 869-878. doi: 10.1007/s12250-021-00360-4
[13]
陈竞芳, 李法卿, 唐家琪, 李先富, 谭维国, 1988: Early Diagnosis of EHF by RPHA, Virologica Sinica, 3, 212-.
[14]
杨占秋, 朱宝莲, 张美英, 1987: INHIBITORY EFFECTS OF RIBAVIRIN AGAINST EPIDEMIC HEMORRHAGIC FEVER VIRUS IN CELL CULTURE, Virologica Sinica, 2, 104-.
[15]
严银芳, 陈晓, 杨小清, 吴少华, 方冬芬, 董长垣, 2002: The Cooperative Anti-influenza Virus Activities of Amantadine， Ribavirin and Herby Houttuynia, Virologica Sinica, 17, 192-194.
[16]
Raouia ElFihry, Mohcine Elmessaoudi-Idrissi, Fatima-Zahra Jadid, Imane Zaidane, Hajar Chihab, Mohamed Tahiri, Mostafa Kabine, Wafaa Badre, Isabelle Chemin, Agnes Marchio, Pascal Pineau, Sayeh Ezzikouri, Soumaya Benjelloun, 2020: Effect of Peroxisome Proliferator-Activated Receptor-γ Coactivator-1 Alpha Variants on Spontaneous Clearance and Fibrosis Progression during Hepatitis C Virus Infection in Moroccan Patients, Virologica Sinica, 35, 566-574. doi: 10.1007/s12250-020-00220-7
[17]
朱智勇, 曾蓉芳, 俞永新, 1991: Efficacy of Inactivated EHF Vaccine Used in Clinical Trial, Virologica Sinica, 6, 315-.
[18]
欧阳学农, 赵允祺, 倪大石, 沈宏开, 1988: Further Studies on HA and HI Test for EHF, Virologica Sinica, 3, 339-.
[19]
王灵枢, 倪大石, 周宁, 1990: Epitope Analysis of Hemagglutinin Antigen with EHF Virus, Virologica Sinica, 5, 125-.
[20]
Sarah L. Londrigan, Gregor Ebert, Prasad N. Paradkar, 2019: Virology at the Lorne Infection and Immunity Conference 2019, Virologica Sinica, 34, 474-474. doi: 10.1007/s12250-019-00115-2